Phase III Clinical Trial Published in New England Journal Of Medicine Identifies New Standards for Prevention of Graft Versus Host Disease Following Transplant
22 juin 2023 11h00 HE
|
Be The Match
MINNEAPOLIS, June 22, 2023 (GLOBE NEWSWIRE) -- Results of a Phase III randomized clinical trial published in the New England Journal of Medicine indicates that a new strategy for prevention of graft...
Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST
23 mars 2023 08h30 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, March 23, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a developer of Next Generation Chemotherapy drugs that provide a better...
Updated Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy
20 déc. 2022 08h50 HE
|
Invectys, Inc.
FDA granted IND clearance for IVS-3001, Invectys’s lead engineered anti-HLA-G CAR-T cell therapy, for the treatment of patients with solid tumors HOUSTON, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) --...
Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy
19 déc. 2022 10h24 HE
|
Invectys, Inc.
FDA granted IND clearance for IVS-3001, Invectys’s lead engineered anti-HLA-G CAR-T cell therapy, for the treatment of patients with solid tumorsHOUSTON, Texas, Dec. 19, 2022 (GLOBE NEWSWIRE) --...
Hospital at Home Program Helping Cancer Patients and Their Families With Medical and Financial Support Services
29 juin 2022 16h00 HE
|
Hospital At Home
CALGARY, Alberta, June 29, 2022 (GLOBE NEWSWIRE) -- As a competitive dancer and avid horseback rider, Lauren Gamble's life changed completely on Aug. 13, 2021. Lauren received an osteosarcoma...
Invectys appoints Timothy Papp as its Chief Financial Officer
12 mai 2022 10h00 HE
|
Invectys, Inc.
Houston, Texas, USA, May 12, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. of Houston, Texas, a clinical stage immunotherapy company dedicated to the development of a next generation of therapies to meet...
Wayne A. Marasco, M.D., Ph.D. joins Invectys’ Scientific Advisory Board
09 mars 2022 10h00 HE
|
Invectys, Inc.
Houston, Texas, USA, March 09, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. of Houston, Texas, a clinical stage immunotherapy company dedicated to the development of a next generation of therapies to...
NHS Cancer Alliance Implements Inspirata AI to Improve Clinical Trial Access for South West Patients
10 févr. 2022 02h59 HE
|
Inspirata, Inc.
Bristol, United Kingdom, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology provider Inspirata and the Somerset, Wiltshire, Avon and Gloucestershire Cancer Alliance (SWAG)...
INVECTYS INC. TO PARTICIPATE IN THE 2021 H.C. WAINWRIGHT 23rd ANNUAL GLOBAL INVESTMENT CONFERENCE SEPTEMBER 13-15, 2021
07 sept. 2021 09h00 HE
|
Invectys, Inc.
Houston, Texas, USA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Invectys Inc. a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products...
INVECTYS INC. TO PARTICIPATE IN THE 2021 ROTH VIRTUAL HEALTHCARE PRIVATE COMPANY FORUM ON JUNE 28TH, 2021
25 juin 2021 11h30 HE
|
Invectys, Inc.
Houston, Texas, USA, June 25, 2021 (GLOBE NEWSWIRE) -- Invectys Inc. a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products...